Amyris ships first fermentation derived cannabinoid to LAVVAN

In California, Amyris successfully shipped the first cannabinoid to its partner, LAVVAN. These ingredients are produced with Amyris’s fermentation technology platform which allows Amyris to scale ingredients that are rarer within the cannabis plant, and difficult and extremely expensive to extract in quantity. Amyris is also well on its way to the shipment of a second cannabinoid in the first half of 2020.

This is the 10th unique fermentation molecule Amyris has currently in production. Amyris is a market leader in Clean Beauty and natural ingredients from fermentation and currently has 22 additional molecules in development with some of the world’s leading companies as partners and long-term supply and commercialization agreements to ensure successful market entry.

The company also announced today that it has agreed on business terms for a partnership with a leading Asian pharmaceutical company to develop and scale a breakthrough target for a rare oncology treatment. In addition to the success in cannabinoids and the new opportunity in oncology the company has also agreed to significantly expand its current collaboration with its Chinese partner for vitamins. Amyris plans to provide further details on these agreements at an investor update meeting to be scheduled in February. These new agreements represent several millions of dollars in collaboration payments annually for the next several years. Biossance is also having an excellent quarter with Biossance.com now representing about 50% of Biossance revenue and Sephora continuing to deliver excellent growth.